AAA
ANRO icon

Affinity Asset Advisors’s Alto Neuroscience ANRO Stock Holding History

Affinity Asset Advisors’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.2M Buy
+500,000
New +$9.27M 0.58% 44

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Affinity Asset Advisors's ANRO Position: Q1 2026 in Review

Affinity Asset Advisors opened a new position in Alto Neuroscience (ANRO) in Q1 2026: 500,000 shares worth $11.2M. The stake represents 0.58% of the portfolio and ranks #44 among its holdings.

110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Affinity Asset Advisors held 500,000 shares of Alto Neuroscience worth $11.2M as of Q1 2026.
  • Alto Neuroscience was a new Affinity Asset Advisors position in Q1 2026.
  • Alto Neuroscience made up 0.58% of Affinity Asset Advisors's portfolio in Q1 2026, its #44 holding.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.